Search Result

Isoforms Recommended:	Akt1 Akt1

Results for "

AKT-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (91) AMPK (4) Apoptosis (22) Autophagy (13) Bacterial (2) Bcl-2 Family (1) Bcr-Abl (1) c-Met/HGFR (2) CaMK (2) Caspase (3) CDK (2) DGK (1) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (1) FAK (1) FXR (1) HPV (1) HSP (2) HSV (2) Insulin Receptor (2) Interleukin Related (1) JNK (1) Keap1-Nrf2 (1) MDM-2/p53 (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (2) mTOR (4) NF-κB (1) NO Synthase (2) Organoid (6) Oxidative Phosphorylation (1) Parasite (2) PDK-1 (3) Phosphatase (1) PI3K (4) PKA (6) PKC (4) PPAR (1) Prostaglandin Receptor (1) PROTAC Linkers (1) PROTACs (7) PTEN (3) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) Ribosomal S6 Kinase (RSK) (6) ROCK (5) Ser/Thr Protease (2) SGK (2) Small Interfering RNA (siRNA) (4) SphK (1) Src (1) STAT (3) VEGFR (2)
By Research Areas:	Cancer (91) Cardiovascular Disease (1) Endocrinology (2) Infection (7) Inflammation/Immunology (10) Metabolic Disease (10) Neurological Disease (2)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

106

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Akt

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146459

Akt1-IN-1	Akt	Cancer
Akt1-IN-1 (compound 5b) is a potent and selective *Akt1* inhibitor with an IC₅₀ value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 µM). Akt1-IN-1 can be used for researching anticancer ^[1].

HY-E70786

AKT1 E17K Recombinant Human Active Protein Kinase	Akt	Cancer
AKT is the oncogenic protein kinase that regulates essential cellular functions such as migration, proliferation, differentiation, apoptosis, and metabolism. Mammalian cells are characterized by the expression of three different Akt isoforms, Akt1, Akt2, and Akt3. AKT1 E17K is a mutant of AKT1. AKT1 E17K Recombinant Human Active Protein Kinase is obtained by expressing AKT1 E17K proteins ^[1].

HY-RS00542

AKT1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
AKT1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT1 Human Pre-designed siRNA Set A AKT1 Human Pre-designed siRNA Set A

HY-RS00544

Akt1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
Akt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt1 Rat Pre-designed siRNA Set A Akt1 Rat Pre-designed siRNA Set A

HY-RS00543

Akt1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
Akt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt1 Mouse Pre-designed siRNA Set A Akt1 Mouse Pre-designed siRNA Set A

HY-161438

Akt1-IN-3	Akt	Cancer
Akt1-IN-3 (Compd 7) is an inhibitor of *AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC₅₀* < 15 nM ^[1].

HY-175716

AKT1-IN-10	Akt	Cancer
AKT1-IN-10 (Compound I-118) is a non-covalent allosteric *AKT1* inhibitor with an IC₅₀ of < 500 μM. AKT1-IN-10 has oral bioavailability.AKT1-IN-10 can be used in cancer ^[1].

HY-163577

Akt1-IN-5	Akt	Cancer
Akt1-IN-5 (Compound 115) is an *Akt1* inhibitor (IC₅₀: <15 nM) ^[1]

HY-163578

Akt1-IN-6	Akt	Cancer
Akt1-IN-6 (Compound 273) is an *Akt1* inhibitor (IC₅₀: <15 nM) ^[1]

HY-163579

Akt1-IN-7	Akt	Cancer
Akt1-IN-7 (Compound 370) is an *Akt1* inhibitor (IC₅₀: <15 nM) ^[1].

HY-173122

Akt1-IN-8	Akt	Cancer
Akt1-IN-8 (Compound JL18) is a potent and oral bioavailable (41%) inhibitor of AKT1 kinase, with an IC₅₀ of 8.8 nM. Akt1-IN-8 exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC₅₀ of 3.0 μM. Akt1-IN-8 can reduce phosphorylated GSK3β levels ^[1].

HY-161439

Akt1-IN-4	Akt	Cancer
Akt1-IN-4 (Compound 62) is an *AKT1-E17K* inhibitor with an IC₅₀ value of less than 15 nM ^[1].

HY-173155

AKT1-IN-9	Akt	Cancer
AKT1-IN-9 (4) is a selective mutant *AKT1(E17K)* inhibitor, with EC₅₀ values of 9 nM and 995 nM in LAPC4-CR and SkBr3 cells, respectively ^[1].

HY-148868A

Akt1&PKA-IN-2	Akt CDK	Cancer
Akt1&PKA-IN-2 ((R)-29) is an inhibitor of *PKB/AKT* with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2 ^a with IC₅₀ values of 0.007 µM, 0.01 µM and 0.69 µM, respectively ^[1].

HY-129119

Akt1/Akt2-IN-2	Akt Caspase	Cancer
Akt1/Akt2-IN-2 (compound 7) is an allosteric dual *Akt1* and *Akt2* inhibitor (IC₅₀=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells ^[1].

HY-50862

Akt1/Akt2-IN-1 2 Publications Verification	Akt	Cancer
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of *Akt1* (IC₅₀=3.5 nM) and *Akt2* (IC₅₀=42 nM), with potent and balanced activity ^[1].

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual *Akt/PKA* inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) ^[1].

HY-16032

Akt1-IN-2	Akt	Cancer
AKT-I-1 is a selective inhibitor of *Akt1, with an IC₅₀* of 4.6 µM ^[1].

HY-RS00545

AKT1S1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
AKT1S1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1S1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT1S1 Human Pre-designed siRNA Set A AKT1S1 Human Pre-designed siRNA Set A

HY-E70790

*Biotin-AKT1* Recombinant Human Active Protein Kinase**	Akt	Cancer
AKT is the oncogenic protein kinase that regulates essential cellular functions such as migration, proliferation, differentiation, apoptosis, and metabolism. Mammalian cells are characterized by the expression of three different Akt isoforms, Akt1, Akt2, and Akt3. Biotin-AKT1 Recombinant Human Active Protein Kinase is obtained by expressing AKT1 proteins and is biotinylated ^[1].

HY-154960

*Tubulin/AKT1-IN-1*	Akt Apoptosis Microtubule/Tubulin	Cancer
Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and *AKT* pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research ^[1].

HY-175848

NSC 850745	c-Met/HGFR STAT Apoptosis Akt VEGFR Bcl-2 Family MDM-2/p53 Caspase	Cancer
NSC 850745 is a selective and potent c-Met/STAT3 inhibitor with IC₅₀ values of 210 and 670 nM. NSC 850745 can inhibit cell proliferation, induce G2/M phase arrest and induce apoptosis. NSC 850745 can downregulate *AKT-1, VEGF* and Bcl-2 expression and upregulate p53, Bax and caspase expression. NSC 850745 can be used for the research of cancer, such as leukemia and colon cancer ^[1].

HY-137458A

Vevorisertib trihydrochloride ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer ^[1].

HY-100018

BAY1125976 1 Publications Verification	Akt	Cancer
BAY1125976, a chemical probe, is a selective allosteric *Akt1/Akt2* inhibitor; inhibits Akt1 and Akt2 activity with IC₅₀ values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

HY-176299

Tanerasertib	Akt	Cancer
Tanerasertib (Compound 456) is an *AKT1* inhibitor with an IC₅₀ of less than 15 nM against AKT1 E17K. Tanerasertib can be used in the study of cancer ^[1].

HY-13254A

A-674563 hydrochloride 5 Publications Verification	Akt	Cancer
A-674563 hydrochloride is a potent and selective *Akt1* inhibitor with K_i of 11 nM.

HY-13254

A-674563 5 Publications Verification	Akt	Cancer
A-674563 is an orally active *Akt1* inhibitor with a K_i of 11 nM.

HY-16666

3CAI 4 Publications Verification	Akt	Cancer
3CAI is a potent and specific *AKT1* and *AKT2* inhibitor.

HY-15431

Capivasertib 70+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and *Akt3*, respectively.

HY-162285

Anticancer agent 189	Akt	Cancer
Anticancer agent 189 (compound 4) is an anticancer agent that antagonizes CRC effects by targeting *AKT1* ^[1].

HY-112148

AKT-IN-2	Akt	Cancer
AKT-IN-2 is a potent, selective and orally bioavailable *AKT* inhibitor with an IC₅₀ of 5 nM for *AKT1* ^[1].

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-15965A

Uprosertib hydrochloride GSK2141795 hydrochloride	Akt	Cancer
Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-19719A

Miransertib hydrochloride 15+ Cited Publications ARQ-092 hydrochloride	Akt Parasite	Infection Cancer
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research ^[1]. Miransertib hydrochloride is effective against Leishmania* .

HY-19719

Miransertib 15+ Cited Publications ARQ-092	Akt Parasite	Infection Cancer
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research ^[1]. Miransertib is effective against Leishmania* .

HY-138767

AKT-IN-5	Akt	Cancer
AKT-IN-5 (Example 8) is a *Akt* inhibitor with IC₅₀ values of 450 nM and 400 nM for *Akt1* and *Akt2*, respectively ^[1].

HY-W750451

Reptoside	Akt	Cancer
Reptoside, an iridoid glucoside, is a DNA damaging active agent. Reptoside has strong interactions with Trp352 and Tyr335 in *AKT1* ^[1].

HY-15727

Afuresertib 15+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively ^[1] .

HY-15727A

Afuresertib hydrochloride 15+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively ^[1] .

HY-169960

2DII	mTOR	Cancer
2DII is a potent and selective mTORC2 inhibitor. 2DII selectively binds mSin1 PH domain and decreases the expression of AKT1 phosphorylation ^[1].

HY-18271

CaMKII-IN-1 5 Publications Verification	CaMK Autophagy	Inflammation/Immunology
CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM; significantly high selectivity against CaMKIV, MLCK, p38a, Akt1, and PKC.

HY-15431R

Capivasertib (Standard)	Akt Autophagy	Cancer
Capivasertib (Standard) is the analytical standard of Capivasertib. This product is intended for research and analytical applications. Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.

HY-151613

MS15	PROTACs Akt	Cancer
MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively ^[1].

HY-143611

AKT-IN-8	Akt	Cancer
AKT-IN-8 is a potent *AKT* inhibitor with IC₅₀s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively ^[1].

HY-138082

Rac-ZINC4085554	Akt FAK	Cancer
Rac-ZINC4085554 is the racemic form of ZINC4085554. ZINC4085554 interferes with the interaction between Akt1 and FAK. ZINC4085554 is useful in colon cancer research ^[1].

HY-10425

Rizavasertib 10+ Cited Publications A-443654	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against *Akt1, Akt2, or Akt3* within cells (K_i=160 pM) ^[1].

HY-151613A

MS15 TFA	PROTACs Akt	Cancer
MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively ^[1].

HY-15186A

Ipatasertib dihydrochloride 50+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for *Akt1, Akt2* and *Akt3*, respectively.

HY-123390

DB07107	Bcr-Abl Akt	Cancer
DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent *Akt1* inhibitor with an IC₅₀ value of 360 nM ^[1] .

HY-19982

AKT-IN-6 1 Publications Verification	Akt	Cancer
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

868 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 868 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P10064

Akt Substrate	Peptides	Others
Akt Substrate (Akt/SKG substrate) is a 7 amino acid synthetic peptide suitable as a substrate for *Akt* .

HY-P5910A

Azurin p28 peptide TFA	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

Recombinant Proteins Recommended:

AKT Serine/Threonine Kinase 1 (AKT1)

Species:	Human (4)
Tag:	His (2) GST (3)
Source:	Sf9 insect cells (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74421

	AKT1 Protein, Human (sf9, His) 5+ Cited Publications RAC-alpha serine/threonine-protein kinase; PKB; RAC-PK-alpha; AKT1; RAC	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (sf9, His) is the recombinant human-derived AKT1 protein, expressed by Sf9 insect cells , with C-10*His labeled tag.

HY-P702631

	AKT1 Protein, Human (Active, sf9, GST) AKT1; v-AKT murine thymoma viral oncogene homolog 1; RAC-alpha serine/threonine-protein kinase; AKT; PKB; PRKBA; RAC; PKB alpha; RAC-PK-alpha; proto-oncogene c-AKT; protein kinase B alpha; rac protein kinase alpha; PKB-ALPHA; RAC-ALPHA; MGC99656	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (Active, sf9, GST) is the recombinant human-derived AKT1, expressed by Sf9 insect cells, with GST labeled tag. The total length of AKT1 Protein, Human (Active, sf9, GST) is 480 a.a..

HY-P704088

	AKT1 Protein, Human (S473D, sf9, His, GST) RAC-alpha serine/threonine-protein kinase; PKB; RAC-PK-alpha; AKT1; RAC	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (S473D, sf9, His, GST) is the recombinant human-derived AKT1 protein, expressed by Sf9 insect cells, with N-His and N-GST labeled tag.

HY-P704293

	AKT1 Protein, Human (GST) AKT 1; AKT; AKT1; AKT1_HUMAN; C AKT; cAKT; MGC99656; PKB alpha; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-AKT; RAC Alpha; RAC; Rac protein kinase alpha; RAC Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; v AKT murine thymoma viral oncogene homolog 1; vAKT Murine Thymoma Viral Oncogene Homolog 1	Human	E. coli
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (GST) is the recombinant human-derived AKT1 protein, expressed by E. coli, with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80008

	AKT1 Antibody (YA634) AKT 1; AKT; AKT1; AKT1_HUMAN ; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha ; Proto-oncogene c-AKT; RAC Alpha;	IHC-P, IHC-F, ICC/IF, IP, FC	Human, Mouse
	AKT1 Antibody (YA634) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1.

HY-P80007

	AKT1 Antibody (YA834) 1 Publications Verification	WB, IHC-P	Human
	AKT1 Antibody (YA834) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AKT1.

HY-P84253

	AKT1 Antibody (YA3950) AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA	WB, ICC/IF, FC, ELISA	Human, Mouse, Monkey, Rat
	AKT1 Antibody (YA3950) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AKT1.

HY-P80535

	AKT1+AKT2+AKT3 Antibody (YA635) AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT1+AKT2+AKT3 Antibody (YA635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1+AKT2+AKT3.

HY-P80009

	AKT1/2/3 Antibody (YA633) 1 Publications Verification	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	AKT1/2/3 Antibody (YA633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1/2/3.

HY-P85561

	AKT1 Antibody (YA5253) AKT 1; AKT; AKT1; AKT1_HUMAN; C AKT; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-AKT; RAC Alpha; RAC; RAC PK Alpha; RAC Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; vAKT Murine Thymoma Viral Oncogene Homolog 1	WB	Mouse, Transfected
	AKT1 Antibody (YA5253) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to AKT1.

HY-P85416

	AKT1 Antibody (YA5108) AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat, Bovine, Chicken, Pig
	AKT1 Antibody (YA5108) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to AKT1.

HY-P84254

	AKT1 Antibody (YA3951) AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA	WB, IHC-P, FC, ELISA	Human, Rat, Monkey
	AKT1 Antibody (YA3951) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AKT1.

HY-P85759

	AKT Antibody (YA5451) AKT1	WB, IP, ICC/IF, ELISA	Human, Mouse, Rat
	AKT Antibody (YA5451) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to AKT.

HY-P86067

	*Phospho-AKT(S473) Antibody (YA5759)* AKT1	WB, IHC-P, ICC/IF	Human
	Phospho-AKT(S473) Antibody (YA5759) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Phospho-AKT(S473).

HY-P80276

	*Phospho-AKT1(Ser473) Antibody (YA227)* 1 Publications Verification AKT 1 antibody; AKT antibody; AKT1 antibody; AKT1_HUMAN antibody; MGC99656 antibody; PKB antibody; PKB-ALPHA antibody; PRKBA antibody; Protein Kinase B Alpha antibody; Protein kinase B antibody; Proto-oncogene c-AKT antibody; RAC Alpha antibody; RAC antibody; RAC-alpha serine/threonine-protein kinase antibody; RAC-PK-alpha antibody;	WB, ICC/IF, IHC-P	Human, Mouse, Rat, Dog
	Phospho-AKT1(Ser473) Antibody (YA227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1(Ser473).

HY-P83434

	PRAS40 Antibody (YA3179) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, IP	Human, Rat
	PRAS40 Antibody (YA3179) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PRAS40.

HY-P86433

	PRAS40 Antibody (YA6125) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PRAS40 Antibody (YA6125) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PRAS40.

HY-P86153

	Phospho-PRAS40(Thr246) Antibody (YA5845) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-PRAS40(Thr246) Antibody (YA5845) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PRAS40(Thr246).

HY-P80788

	*Phospho-AKT1* (Ser473) Antibody (YA228)** 2 Publications Verification AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat
	Phospho-AKT1 (Ser473) Antibody (YA228) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1 (Ser473).

HY-P80789

	*Phospho-AKT* (Thr308) Antibody** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	Phospho-AKT (Thr308) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-AKT (Thr308).